Thus, targeting of TGF‐β receptors with soluble TGF‐β receptor II, small molecule ALK5 kinase inhibitors, or neutralizing TGF‐β1 antibodies have been reported to exhibit some therapeutic effect on cancer.2 The gene discussed is TGFB1; the disease is cancer.